Triple threat: new combo therapy targets Hard-to-Treat melanoma
NCT ID NCT02910700
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial is testing two different three-drug combinations in people with advanced BRAF-mutated melanoma that has spread or cannot be removed by surgery. One group receives nivolumab (immunotherapy) plus dabrafenib and trametinib (targeted therapy); the other receives nivolumab plus encorafenib and binimetinib. The goal is to see how well these combinations shrink tumors and what side effects occur. The study enrolls 52 participants whose melanoma has progressed after prior PD-1 therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dabrafenib, nivolumab, trametinib, binimetinib, encorafenib
What this could lead to
If successful, this could offer a new treatment option for people with advanced BRAF-mutated melanoma that has stopped responding to standard immunotherapy.
What could go wrong
This is a small, early-phase trial (52 participants) testing two different drug combinations. Side effects from combining targeted therapy and immunotherapy can be significant, and it is not yet known if these combinations work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT NEOPLASM IN THE BRAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States